Research programme: RAP-3 targeted cancer therapeutics - RicercaAlternative Names: RAP-3 targeted cancer therapeutics research programme - Ricerca
Latest Information Update: 07 Oct 2004
At a glance
- Originator Serono Genetics Institute
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Oct 2004 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 09 Jul 2004 Preclinical trials in Cancer in USA (unspecified route)